Purpose of review Allergen immunotherapy (AIT) is currently the only curative treatment available for allergic diseases, and has been used in clinical practice for over a century. Induction and maintenance of immune tolerance to nonhazardous environmental and self-antigens is essential to maintain homeostasis and prevent chronic 
INTRODUCTION
Allergen immunotherapy (AIT) has been used as a curative treatment for allergies for more than a century and many of its underlying mechanisms have been elucidated. These include early desensitization of mast cells and basophils, induction of Regulatory T (T REG ) cells, production of allergenspecific IgG (particularly IgG4) antibodies, suppression of eosinophil activation and migration [1, 2] . In addition, several recent studies suggest a potential role for regulatory B (B REG ) cells in AIT [3] .
PHENOTYPE AND FUNCTION OF REGULATORY B CELLS
B REG cells exhibit anti-inflammatory functions, and their immunosuppressive role has been demonstrated to varying degrees in autoimmune disease, cancer, transplantation, infection, and allergic inflammation [3, 4] .
SUPPRESSIVE MECHANISMS OF REGULATORY B CELLS
B REG cells act primarily through secretion of the immune-modulatory cytokines [3] . Most studies have focused on the role of IL-10 as the key factor through which B REG cells modulate immune responses and protect against excessive inflammation [5] [6] [7] [8] [9] [10] . IL-10 has a wide range of suppressive effects on different cells types and has been widely recognized as an immune tolerance-inducing factor in patients with different chronic inflammatory diseases [11] . Transforming growth factor-b (TGF-b) has also been identified as B REG -associated suppressor molecule. TGF-b is involved in many processes including tissue remodelling and immune regulation. An important role for TGF-b in the context of immune tolerance is its capacity to support conversion of naive CD4 þ T cells to T REG cells [11] . Finally, IL-35 has also been linked to B REG -mediated immune suppression [12] . IL-35 can promote immune tolerance through induction of T REG proliferation and suppression of T H 17 responses [11] .
Apart from secreted cytokines, other molecules have been associated with B REG -mediated suppressive effects. These include the membrane-associated molecules such as CD19 [13] , CD62L and MHC-II [14] , fas ligand [15] , T-cell immunoglobulin and mucin domain [16] , and programmed death ligand 1 [8, [17] [18] [19] [20] , as well as the intracellular signalling molecules signal transducer and activator of transcription 3 and myeloid differentiation response gene 88 [21] .
In the context of human allergen tolerance induction, the production of IgG4 antibodies deserves some attention. IgG4 is considered to compete with IgE for allergen binding and therefore may function as a blocking antibody. Some unique features of IgG4 such as antigen-binding fragment-arm exchange, its low affinity for activating fragment crystallizable receptors, and its inability to fix complement render IgG4 an anti-inflammatory immunoglobulin isotype [22, 23] .
One of the mechanisms through which B REG cells could play a role in AIT, is through the modulation of T-cell responses. B REG cells have been shown to induce T REG cells in several different models [3, 24, 25] . Apart from induction of T REG cells, B REG cells could support AIT through suppression of effect T-cell proliferation and cytokine production [8, 26] . A recent study provided compelling data demonstrating that B REG cells could modulate T follicular helper (T FH ) cell responses. Cocultures of in-vitro generated human T FH cells with B cells resulted (as expected) in plasma cell and memory cell differentiation. Upon addition of B cells that were stimulated for 3 days with CD40L and TLR9-ligand CpG2006 (these cells were considered B REG in this study), the B-cell differentiation was inhibited, and forkhead box (FoxP)3
þ programmed death ligand-1 þ regulatory T FH were expanded. CD40, CD80, CD86, as well as IL-10 and TGF-b played a role in this process. These findings suggest that B REG cells can interfere with germinal centre reactions through modulation of T FH cells [27 & ] . A weakness in this study is the fact that stimulated total B cells were used as B REG , whereas only a fraction of these cells can be considered B REG cells. Some of these findings were corroborated in a murine cardiac transplantation model, in which marginal zone B-cell-derived IL-10 proved essential for induction of regulatory T FH cells and tolerance toward the allograft [28] .
DIFFERENT SUBSETS OF REGULATORY B CELLS
A number of different human and murine B REG cells have been identified based on phenotypic and functional characteristics. It goes beyond the scope of this review to describe all B REG subsets in detail and comprehensive reviews on this topic have been published elsewhere [3, 4] . In the mouse system, B REG cells are found among cells with a B1a-like cells (i.e. CD5
þ B cells) [29] , among B cells with an immature/transitional phenotype [30, 31] , and among cells with a plasma cell phenotype [32] . In the human system, the major phenotypes of B REG cells are CD27
hi immature B cells [20] , CD73
þ/hi plasmablasts [3, 17, 32] . 
REGULATORY B CELLS AND THEIR ROLE IN TOLERANCE INDUCTION TO ALLERGENS

REGULATORY B CELLS IN INDUCTION AND MAINTENANCE OF TOLERANCE TO ALLERGENS IN HUMANS
The aim of AIT is typically to restore clinical and immunological tolerance to allergens [36] . This requires the alteration of a T H 2 and IgE-dominated allergic response toward a healthy immune response. Healthy immune responses to allergens have been studied primarily in cat owners and beekeepers. Hallmarks of a healthy response to allergens are induction of IL-10-producing inducible type 1 regulatory T (T R 1) cells and blocking IgG(4) antibodies [37] .
A human B REG subset that has been studied in the context of tolerance to allergens are
. These cells could efficiently suppress antigen-specific CD4 þ T-cells proliferation. Data supporting a role for human B REG cells in developing tolerance to allergens comes primarily from studies on bee venom allergic individuals and healthy beekeepers. B cells specific for the major bee venom allergen phospholipase A2 (PLA) were identified using fluorescently labelled PLA. The frequency of IL-10-producing B cells among these allergen-specific B cells showed a two to five-fold increase in bee venom allergic patients at 3-4 months after the start of venom immunotherapy (VIT). After this increase the frequency of PLA-specific IL-10-producing B cells was at a comparable level as in healthy beekeepers during the season [8] . It remains to be elucidated whether allergen-specific B cells upregulate IL-10 production during VIT, or preexisting IL-10-producing allergen-specific B cells proliferate during VIT. Apart from IL-10, allergen-specific B cells also upregulated C-C chemokine receptor (CCR) 5 þ allergen-specific B cells [8] . In accordance with increases in serum levels of allergen specific IgG4 of that are frequently observed during AIT [36] , it was primarily expansion of allergen-specific IgG4-switched B cells that drove this increase of allergen-specific B cells during VIT [34 & ]. Increases in specific IgG4 during AIT correlate with clinical outcome in some, but not all studies [36] . One intriguing possibility is that not just an increase of specific IgG4 is sufficient for clinical improvement but rather the generation of high-affinity-specific IgG4 antibodies. This concept is technically challenging to prove, but recent work indicates that IgG4 (but not IgE)-switched peanut allergen-specific B cells accumulate an increasing proportion of more highly mutated sequences over time during the course of peanut oral immunotherapy [40 && ]. As increased levels of somatic mutations are indicative of affinity maturation [41] , these data suggest that IgG4 antibodies increase their affinity during AIT.
Very interesting in the context of a potential role for B REG cells during AIT is the link between IL-10-producing B R 1 cells and IgG4 production. Purified IL-10-producing B cells produced significantly increased levels of IgG4 antibodies compared to IL-10 À B cells, whereas other immunoglobulin isotypes were produced in comparable amounts by IL-10 þ and IL-10 À cells [8] . Thus, B R 1 may promote allergen tolerence during AIT through IL-10-mediated suppressive effects and through directing the humoral response toward IgG4.
REGULATORY B CELLS IN MOUSE MODELS OF TOLERANCE INDUCTION IN ALLERGIC AIRWAY INFLAMMATION
B cells can induce allergen tolerance through production of TGF-b as was demonstrated in an ovalbumin (OVA)-induced airway inflammation and tolerance model. Mice that were administered a short-term (7 day) daily intranasal OVA exposure developed sensitization, whereas chronically exposed mice (42-day exposure) developed tolerance. Adoptively transferred B cells isolated from hilar lymph nodes of chronically exposed mice suppressed allergic airway inflammation in sensitized recipient mice. This suppressive effect was independent of IL-10, as B cells isolated from tolerant IL-10 À/ À mice exerted similar suppressive capacity [42] . Later it was found that CD5 þ
CD1d
hi B cells were expanded in hilar lymph nodes of tolerant mice. These cells produced TGF-b and induced FoxP3 expression in CD4 þ T cells in vitro and suppressed development of allergic airway inflammation in vivo via enhanced accumulation of Foxp3 þ T cells in the lung [24] .
A recent study with a different approach demonstrated that development of OVA-induced airway inflammation and tolerance induction were developed similarly in wild-type (WT) and B cell-deficient (mMT) mice, indicating that B cells are not required for establishing OVA-induced airway inflammation. Tolerance could be induced by pretreatment with a high dose of intranasally administered OVA both in WT and mMT mice, suggesting that B cells were dispensable for tolerance induction in this model. IL-10 production by purified splenic B cells in response to lipopolysaccharide stimulation from OVA-sensitized and tolerized showed a similar and modest increase compared with control mice [25] . The effect of TGF-b production was not assessed in this study. It is interesting to note here that OVA-induced airway inflammation was accompanied by elevated germinal centre B cells numbers and elevated specific immunoglobulin production, whereas these B cell alterations were attenuated upon tolerance induction. Moreover, marginal zone precursor B cells from tolerant mice could induce T REG cells in vitro [25] .
Methodological differences (e.g. application routes, dosing schemes, B cell-deficient mice vs. adoptive transfer experiments) may partially explain the seemingly different conclusions of these studies. However, taken together these datapoint out that in high-dose OVA tolerance induction models for allergic airway inflammation, B REG cells can be induced or expanded. These B REG cells have the capacity to induce T REG cells and, upon adoptive transfer, confer allergen tolerance in sensitized recipient mice in an IL-10-independent manner. TGF-b could be the driving factor in this process. These B REG cells may therefore contribute to allergen-tolerance induction in such an AIT model but the fact that B cell-deficient mice still develop tolerance indicates that there is redundancy with other suppressor cells. 
CX3CR1
þ B cells could ameliorate T H 2-mediated intestinal inflammation [26] . A factor that may promote TGF-b production by B cells is thrombospondin 1, which enhances generation of active TGF-b. When mice sensitized with OVA and cholera toxin (to induce intestinal inflammation) received an AIT regimen in the form of increasing doses of gavage-fed OVA, CD35 þ B cells in the lamina propria increased in frequency and produced thrombospondin 1 [43] .
CONCLUSION
AIT has been used with considerable success for over a century. Increasingly detailed knowledge has been accumulated on the immunological mechanisms that drive successful clinical outcome of this therapy. B REG cells have only recently been identified as potentially relevant cells in the induction and maintenance of allergen tolerance. Currently available data suggest potential roles for B REG cells in AIT treatment of allergic airway inflammation, food allergies, and venom allergies. Mechanisms through which B REG cells may contribute to tolerance induction during AIT are summarized in Fig. 1 and include IL-10-mediated suppression of effector T cell, including T H 2 responses [8, 26] , induction of T REG cells [24, 25] , IL-10-mediated inhibition of DC maturation [44] 
